NCT05211570: AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 78 planned
- Started
- 1 Jun 2022
- Primary completion
- Aug 2026
- Arms
- AB8939 plus Venetoclax
- Results
- None posted
- 27 Jan 2022: Trial registered
- 1 Jun 2022: Trial started